Regeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M
Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally